In the SAFE-HEaRt study, patients with stage 1 to 4 HER2 positive breast cancer were candidates for treatment with trastuzumab, pertuzumab or ado-trastuzumab and had LVEF between 40 and 49% (without symptoms of heart failure). The gene discussed is ERBB2; the disease is breast cancer.